LATISHA ALI: Open Payments
NPI 1295217198 · HOOVER, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,918 in 130 payments from 14 companies in 2025. Trend: 2023 $3,260 · 2024 $3,037 · 2025 $2,918
Food & beverage: $2,918
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 23 | $565 |
| Otsuka America Pharmaceutical, Inc. | 18 | $424 |
| Janssen Pharmaceuticals, Inc | 14 | $340 |
| Axsome Therapeutics, Inc. | 12 | $334 |
| ABBVIE INC. | 20 | $232 |
| Neurocrine BioSciences, Inc. | 8 | $218 |
| Vanda Pharmaceuticals Inc. | 8 | $190 |
| Lundbeck LLC | 7 | $178 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $143 |
| Alkermes, Inc. | 5 | $125 |
Products named: REXULTI, CAPLYTA, Auvelity, VRAYLAR, INGREZZA, FANAPT, INVEGA SUSTENNA, SPRAVATO.
Industry payments across AL — which companies pay providers there.
